Streetbeat News

Products Services

NVS

The US FDA has approved Novartis' Fabhalta for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN).

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 6:22 pm

IREN

Iris Energy Limited (NASDAQ:IREN) shares are trading lower after the company issued its July 2024 investor update. The update revealed a decrease in Bitcoin mining output and operational challenges, but also highlighted growth in AI Cloud Services revenue and future expansion plans.

Portfolio Pulse from Dylan Berman

August 07, 2024 | 6:20 pm

EXEL

Exelixis, Inc. (NASDAQ:EXEL) announced mixed results from its phase 3 CONTACT-02 trial, showing significant progression-free survival but not overall survival. Despite this, the company plans to submit a supplemental marketing application to the FDA in 2024. Exelixis reported strong Q2 earnings, beating both EPS and sales expectations, and raised its 2024 revenue guidance. An analyst from William Blair reiterated an Outperform rating, citing the company's defensive investment profile.

Portfolio Pulse from Vandana Singh

August 07, 2024 | 6:16 pm

DOGEUSD

PYPL

Elon Musk's plan to transform X (formerly Twitter) into an everything app with payment features is advancing. A new report indicates that X has added a Payments button and obtained a license in North Dakota, bringing its total to 33 states. The launch of X payments could boost engagement and potentially increase the price of Dogecoin. X could also compete with online payment companies like PayPal.

Portfolio Pulse from Chris Katje

August 07, 2024 | 6:06 pm

AMGN

Amgen Inc. (NASDAQ: AMGN) reported mixed Q2 results, with analysts focusing on the potential of its obesity drug, MariTide. Despite underperformance in its base business, analysts remain optimistic about Amgen's long-term growth prospects, maintaining positive ratings and high price targets.

Portfolio Pulse from Vandana Singh

August 07, 2024 | 6:01 pm

NVO

Novo Nordisk (NYSE:NVO) reported second-quarter earnings that missed analyst expectations and announced the withdrawal of its Wegovy FDA heart failure submission. The company plans to resubmit the file in 2025 with additional data. Novo Nordisk also terminated the development of two early-stage assets. Despite a 25% increase in sales, the stock fell 7.73% due to the earnings miss and regulatory setbacks.

Portfolio Pulse from Vandana Singh

August 07, 2024 | 5:55 pm

AMZN

FXI

PDD

Amazon is developing a network of Chinese sellers to compete with Temu and Shein. This move aims to enhance Amazon's product offerings and attract more customers by leveraging the competitive pricing and variety of Chinese goods.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 5:38 pm

BNOX

Bionomics has received a Notice of Allowance for a US patent on substituted-N-heteroaryl compounds, which are intended for improving cognitive function and treating CNS disorders.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 5:23 pm

AAPL

Apple and Major League Baseball have announced the September schedule for 'Friday Night Baseball,' which will be available on Apple TV+. This partnership continues to enhance Apple's content offerings and attract sports fans to its streaming platform.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 5:22 pm

BTCUSD

SOLUSD

Solana (SOL) has outperformed Bitcoin (BTC) over the past month, with an 8.5% increase compared to Bitcoin's 0.5% return. Crypto traders are optimistic about Solana's potential to reach new local highs if it surpasses current resistance levels. However, caution is advised due to potential vulnerabilities in built-up lows.

Portfolio Pulse from Khyathi Dalal

August 07, 2024 | 5:20 pm